Clinical trials: Remission
Crohn Disease
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.
- Trial name
- NCT00206674
- Testing
- Sargramostim (Leukine)
- Where
- 70 sites in Argentina, Australia and 7 more
- Volunteers
- 286 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission [CR], complete remission…
- Trial name
- NCT03070093
- Testing
- gilteritinib
- Where
- 39 sites in United States, Canada and 1 more
- Sponsor
- Astellas Pharma Global Development, Inc.
Rheumatoid Arthritis
Study Evaluating the Clinical Remission in Early Aggressive Rheumatoid Arthritis
This is an observational prospective, multicenter study. The aim of the study is to evaluate how the Italian population of patients are treated with early aggressive RA, defined by the Italian Society of Rheumatology Guidelines…
- Trial name
- ARPA (NCT00267852)
- Testing
- as clinical practice
- Where
- 16 sites in Italy
- Volunteers
- 152 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in participants who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.
- Trial name
- NCT01510184
- Testing
- Zevalin, Y-90-Zevalin, Rituximab
- Where
- 93 sites in United States, Australia and 11 more
- Volunteers
- 79 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
The purpose of this study is to provide expanded access to gilteritinib (ASP2215) for patients with FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed or refractory acute myeloid leukemia (AML) or with FLT3-mutated AML in…
- Trial name
- NCT03409081
- Testing
- gilteritinib
- Where
- 6 sites in Australia, Italy and 1 more
- Sponsor
- Astellas Pharma Global Development, Inc.
Ulcerative Colitis
A Comparison of Once a Day Dose Compared to 2 Doses/Day
The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.
- Trial name
- NCT00505778
- Testing
- Mesalamine Once-Daily, Mesalamine Twice-Daily
- Where
- 245 sites in United States, Canada and 1 more
- Volunteers
- 1,027 people
- Sponsor
- Warner Chilcott
Diabetes Mellitus Type 2 in Obese, Hypertension
Vegetarian Ketogenic Diet VS Omnivore Ketogenic Diet - Protocol of a Keto-vege Diet for Remission of Type 2 Diabetes
Diabetes is one of the biggest public health challenges of the 21st century because of the costs associated with its management, which are estimated at more than three billion dollars per year in Quebec.
- Conditions
- Diabetes Mellitus Type 2 in Obese, Hypertension, Diabetes Mellitus Type 2 With Hyperglycemia, Inflammation
- Trial name
- DT2-OFF (NCT05579561)
- Testing
- Diet
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- BloomedIn
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Focal Segmental Glomerulosclerosis
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
- Trial name
- AURONA™ (NCT03598036)
- Testing
- Voclosporin
- Where
- 23 sites in United States, Dominican Republic
- Volunteers
- 5 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Crohn Disease
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 [NCT00552058].
- Trial name
- NCT00552344
- Testing
- Cimzia
- Where
- 100 sites in United States, Australia and 16 more
- Volunteers
- 403 people
- Sponsor
- UCB BIOSCIENCES GmbH
Incomplete Microscopic Colitis
Budesonide for Induction of Remission in Incomplete Microscopic Colitis
The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of active incomplete microscopic colitis.
- Trial name
- NCT02142634
- Testing
- Budesonide granules 9 mg
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 44 people
- Sponsor
- Dr. Falk Pharma GmbH
Diabetes Mellitus, Type 2
Digital, Blended Lifestyle Intervention for Type 2 Diabetes Remission
410 Dutch type 2 diabetes patients will be randomized using a 5:1 ratio to intervention group versus control, to a lifestyle intervention program given via a mobile application and digital platform.
- Trial name
- IBIDEM (NCT05346614)
- Testing
- Lifestyle intervention
- Where
- 4 sites in Netherlands
- Volunteers
- 410 people
- Sponsor
- Ancora Health B.V.
Epithelial Ovarian Cancer
Ovarian Cancer Vaccine for Patients in Remission
The purpose of this study is to determine the safety and efficacy of an investigational therapeutic agent (Cvac) in ovarian cancer patients in first or second remission and to determine its ability to prevent cancer from…
- Trial name
- NCT01068509
- Testing
- Cvac
- Where
- 18 sites in United States, Australia
- Volunteers
- 63 people
- Sponsor
- Prima BioMed Ltd
Systemic Lupus Erythematosus
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without…
- Trial name
- SUNFLOWER (NCT07430306)
- Testing
- Anifrolumab
- Where
- 107 sites in United States, Canada and 7 more
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)
The aim of this study is to evaluate the complete remission rates, endoscopic relapses, study discontinuation rates, and quality of life parameters in patients with erosive GERD.
- Trial name
- NCT00325676
- Testing
- Pantoprazole
- Where
- 45 sites in Brazil, Germany and 2 more
- Volunteers
- 639 people
- Sponsor
- Takeda
Eosinophilic Esophagitis
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in…
- Trial name
- EOS-4 (NCT06596252)
- Testing
- Budesonide
- Where
- 21 sites in United States, Spain
- Volunteers
- 308 people
- Sponsor
- Dr. Falk Pharma GmbH
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01375478
- Where
- 13 sites in Greece
- Volunteers
- 197 people
- Sponsor
- Hoffmann-La Roche
Bipolar Disorder
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
The precursor study (SCA101469) was an open-label, prospective multicentre study in adult subjects diagnosed with bipolar disorder consisting of 36 weeks treatment with lamotrigine.
- Trial name
- NCT00360126
- Testing
- lamotrigine
- Where
- 3 sites in Australia
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
- Trial name
- MAPUS (NCT01951326)
- Testing
- RHB-104
- Where
- 103 sites in United States, Australia and 8 more
- Volunteers
- 331 people
- Sponsor
- RedHill Biopharma Limited
Ulcerative Colitis
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
This is a multi-center, randomized, parallel arm, double-blind study with approximately 750 participants with moderately to severely active Colitis Ulcerosa randomized to receive either PB016 or Entyvio®
- Trial name
- UCESIVE (NCT05771155)
- Testing
- Intravenous (IV) infusions
- Where
- Georgia
- Volunteers
- 750 people
- Sponsor
- Polpharma Biologics S.A.